Bayer's Courtroom Win and Q3 Test: JPMorgan, Deutsche Bank Split on the Quarter but Agree on the Target

Judge rejects Pfizer, BioNTech and Moderna dismissal bids in Bayer's mRNA patent cases; JPMorgan and Deutsche Bank flag a soft third quarter.

A federal judge in the United States has handed Bayer a procedural victory in its patent fight over COVID-19 vaccine technology, even as the German conglomerate braces for a quarterly earnings report that two major investment banks expect to land softly.

Judge William Bryson rejected motions from Pfizer, BioNTech and Moderna seeking early dismissal of patent infringement suits filed by Bayer and its subsidiary Monsanto, according to Reuters. The ruling, dated 28 September, allows the mRNA technology cases to proceed on the merits — a rare piece of good news for a company whose legal calendar has been dominated by glyphosate litigation for years.

Investors responded with measured optimism. Bayer shares changed hands at EUR 44.81 on Tuesday, up 1.7% on the day and sitting 3.8% above their 200-day moving average of EUR 43.17.

A Pipeline in Motion, a Quarter Under Scrutiny

While the patent cases advance, Bayer's pharmaceutical division is generating its own momentum. The FDA and the European Medicines Agency have both granted orphan drug designation to lemiretprocel, a development candidate from subsidiary BlueRock Therapeutics. In a separate move, the company installed Dr. Christoph Koenen as Chief Medical Officer effective 1 October, a role he holds alongside his existing responsibilities as head of clinical development and pharmaceutical operations.

Those pipeline developments, however, are unlikely to shift the near-term narrative. Attention is fixed on 3 November, when Bayer publishes its third-quarter results — and on the question of whether the agricultural unit's order timing will produce a temporary dip or something more troubling.

Two Banks, One Warning

Richard Vosser of JPMorgan rates the stock Overweight with a price target of EUR 61, but cautioned that market expectations for the third quarter may be set too high. He attributes the likely shortfall primarily to timing shifts in the crop science business, while stressing that full-year estimates should barely move as a result. Virginie Boucher-Ferte of Deutsche Bank Research reaffirmed her Buy rating and EUR 60 target on 29 September, also flagging a year-on-year decline in operating profit driven by prior-year base effects.

The distinction matters. Shifts in crop protection orders are routine in agriculture; a genuine drop in volumes would be a different story entirely. If farmers have merely delayed purchases, the fourth quarter should absorb the catch-up. If they have cut order sizes in response to changed market conditions, the earnings framework weakens — and the market will demand a clear confirmation on 3 November that the expected rebound remains achievable.

Legal Overhang Persists

The patent win does not erase Bayer's broader litigation exposure. Court approval of the USD 7.25 billion US settlement framework is still pending, and glyphosate concerns resurfaced recently, weighing on the share price. In Germany, political discussions about requiring pharmaceutical manufacturers to contribute to wastewater treatment costs add another layer of uncertainty. A new Roundup trial opened roughly a week ago in St. Louis, where a jury is hearing claims from three women alleging design defects.

Chart Levels Frame the Decision

Technically, the picture is mixed. The stock trades at EUR 44.44, below its 50-day moving average of EUR 48.48, yet remains above the 200-day line at EUR 43.17 — the threshold that has defined this year's broader uptrend. Holding that support gives investors room to weigh strategic progress against near-term risks. A break below it would open the door to deeper consolidation zones.

Bayer has also bolstered its financial flexibility, having placed EUR 2 billion in hybrid bonds in September. Combined with the announced multibillion-dollar investment in a new US pharmaceutical production site in Ohio, the company is signalling a long-term repositioning even as the market focuses on the next set of numbers.

Between now and 3 November, volatility is likely to stay elevated. The quarter itself may prove less important than what management says about the fourth — and whether the annual guidance survives contact with reality.